Surgical treatment for hepatocellular carcinoma and concomitant esophagogastric varices
โ Scribed by Akio Harada; Toshiaki Nonami; Akimasa Nakao; Tsuyoshi Kurokawa; Hiroshi Takagi
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 400 KB
- Volume
- 12
- Category
- Article
- ISSN
- 8756-0437
No coin nor oath required. For personal study only.
โฆ Synopsis
Preventing a rupture of esophagogastric varices (EGV) is very important in aggressively treating hepatocellular carcinoma (HCC) in cirrhotic patients. We therefore performed simultaneous partial hepatic resection and direct interruption procedure on nine patients with HCC and concomitant EGV. Patients were selected on the basis of their stages of HCC and hepatic functional reserve. Postoperative hospital courses of all patients were uneventful. Six patients had recurrence of HCC and received non-surgical anti-tumor treatments. Only one patient had upper gastrointestinal bleeding at 18 months after operation, and the other eight patients have had no episodes of upper gastrointestinal bleeding during the follow-up period. The 5-year survival rate of these patients was 48%. This operative procedure is quite effective and is one of the treatments of choice for patients with less advanced HCC and concomitant risk of EGV.
๐ SIMILAR VOLUMES
Vascular invasion and high histologic grade predict poor outcome after surgical resection or liver transplantation for hepatocellular carcinoma (HCC). Despite the known association between tumor size and vascular invasion, a proportion of patients with large tumors can be treated surgically with exc
Liver transplantation is proposed as the best therapy for early hepatocellular carcinoma in cirrhotic patients. However, the confrontation with the results obtained by surgical resection has never been done on an intention-to-treat basis. Between 1989 and 1997, 164 out of 1,265 patients with hepatoc
We read with interest a paper by Kudo et al. published in a recent issue of HEPATOLOGY that compared the predictive power between Japan Integrated Staging (JIS) system and Cancer of the Liver Italian Program (CLIP) system in a large patient cohort with hepatocellular carcinoma (HCC). 1 The authors c